Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine

Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine

Abstract Prostate adenocarcinoma (PRAD) is a leading cause of death among men. Messenger ribonucleic acid (mRNA) vaccine presents an attractive approach to achieve satisfactory outcomes; however, tumor antigen screening and vaccination candidates show a bottleneck in this field. We aimed to investig...

Full description

Bibliographic Details
Main Authors: Xiaonan Zheng, Hang Xu, Xianyanling Yi, Tianyi Zhang, Qiang Wei, Hong Li, Jianzhong Ai
Format: Article
Language:English
Published: BMC 2021-12-01
Series:Molecular Cancer
Subjects:
mRNA vaccine
Prostate adenocarcinoma
Immunotherapy
Tumor antigens
Immune subtypes
Immune landscape
Online Access:https://doi.org/10.1186/s12943-021-01452-1

Internet

https://doi.org/10.1186/s12943-021-01452-1

Similar Items